GlassScriptPhysician profile
James A Halikas
NPI 1841399318
$1,438.89
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $392 · 2021: $64.27 · 2022: $151 · 2023: $244 · 2024: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $344.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $331.01 | 2021-2023 | |
| Allergan, INC. | $272.77 | 2019-2020 | |
| Indivior INC. | $172.33 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $121.83 | 2019 | |
| Axsome Therapeutics, INC. | $100.29 | 2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.00 | 2020 | |
| Neurocrine Biosciences, INC. | $99.93 | 2023 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $53.88 | 2019 | |
| Bausch Health US, LLC | $39.62 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $28.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.59 | 2019 | |
| Arbor Pharmaceuticals, INC. | $19.27 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $15.66 | 2020 | |
| Almatica Pharma LLC | $14.12 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $13.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Halikas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.